Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.80 |
| ▸ | RECQL | P46063 | 3/20 | 0.80 |
| ▸ | BLM | P54132 | 3/20 | 0.80 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.80 |
| ▸ | THRB | P10828 | 2/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.80 |
| ▸ | CDK2 | P24941 | 1/20 | 0.80 |
| ▸ | CHAT | P28329 | 1/20 | 0.80 |
| ▸ | BLVRB | P30043 | 1/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | GNG2 | P59768 | 1/20 | 0.51 |
| ▸ | GNB1 | P62873 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30160703 | 1.00 | MEN1 (0.80) | MEN1KMT2ATDP1RECQLBLM | |
| Erythrosine SCHEMBL29353687 | 0.89 | MEN1 (1.00) | MEN1KMT2ATDP1RECQLBLM | |
| Erythrosine SCHEMBL29356181 | 0.89 | MEN1 (1.00) | MEN1KMT2ATDP1RECQLBLM | |
| Erythrosine SCHEMBL25042 | 0.89 | MEN1 (1.00) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL5364186 | 0.89 | MEN1 (0.62) | MEN1KMT2ATDP1RECQLBLM | |
| Erythrosine SCHEMBL1461335 | 0.88 | MEN1 (0.97) | MEN1KMT2ATDP1RECQLBLM | |
| Erythrosine SCHEMBL18526925 | 0.88 | MEN1 (0.97) | MEN1KMT2ATDP1RECQLBLM | |
| Erythrosine SCHEMBL250944 | 0.88 | MEN1 (0.97) | MEN1KMT2ATDP1RECQLBLM | |
| Erythrosine SCHEMBL3686955 | 0.88 | MEN1 (0.97) | MEN1KMT2ATDP1RECQLBLM | |
| Erythrosine SCHEMBL29827300 | 0.88 | MEN1 (0.97) | MEN1KMT2ATDP1RECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281180-B2 | Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2025-04-22 | — | — | US | disclosed |
| US-12133840-B2 | Halogenated xanthene composition and method for treating hematologic cancers | PROVECTUS PHARMATECH, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240316191-A1 | Halogenated Xanthenes as Vaccine Adjuvants | Provectus Pharmatech , Inc. (US) | 2024-09-26 | — | — | US | disclosed |
| US-12064507-B2 | Composition and method for oral treatment of leukemia | PROVECTUS PHARMATECH, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-11975106-B2 | Uses of halogenated xanthenes in oncology and virology | PROVECTUS PHARMATECH, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11938182-B2 | Halogenated xanthenes as vaccine adjuvants | PROVECTUS PHARMATECH, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240082206-A1 | Composition and Method for Treating Hematologic Cancers | PROVECTUS PHARMATECH, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3773548-B1 | IN VITRO AND XENOGRAFT ANTI-TUMOR ACTIVITY OF A HALOGENATED-XANTHENE AGAINST REFRACTORY PEDIATRIC SOLID TUMORS | PROVECTUS PHARMATECH INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11426379-B2 | Combination of local and systemic therapies for enhanced treatment of dermatologic conditions | PROVECTUS PHARMATECH, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11419844-B2 | Halogenated xanthene composition and method for treating hematologic cancers | PROVECTUS PHARMATECH, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220054449-A1 | Combination Of Local And Systemic Therapies For Enhanced Treatment of Dermatologic Conditions | THE ROCKEFELLER UNIVERSITY (US) | 2022-02-24 | — | — | US | disclosed |
| WO-1994020850-A1 | pH-ZONE-REFINING COUNTERCURRENT CHROMATOGRAPHY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5332504-A | Acidification and basification of liquids and centrifuging | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064507-B2 | Composition and method for oral treatment of leukemia | MCL1, BCL6, CD47 | MEN1 1401/4885KMT2A 2902/4885TDP1 1159/4885 |
| US-20240316191-A1 | Halogenated Xanthenes as Vaccine Adjuvants | IFNG, IRF3, STING1 | MEN1 869/4885KMT2A 3435/4885TDP1 725/4885 |
| US-20220054449-A1 | Combination Of Local And Systemic Therapies For Enhanced Treatment of Dermatologic Conditions | CYP24A1, CYP2R1, IL23R | MEN1 4290/4885KMT2A 3950/4885TDP1 2213/4885 |
| US-11938182-B2 | Halogenated xanthenes as vaccine adjuvants | IFNG, IRF3, STING1 | MEN1 869/4885KMT2A 3435/4885TDP1 725/4885 |
| US-11419844-B2 | Halogenated xanthene composition and method for treating hematologic cancers | ETV6, BCL6, XPA | MEN1 473/4885KMT2A 2095/4885TDP1 1496/4885 |
| US-20240082206-A1 | Composition and Method for Treating Hematologic Cancers | BCL6, CD47, ETV6 | MEN1 283/4885KMT2A 2677/4885TDP1 1167/4885 |
| US-12133840-B2 | Halogenated xanthene composition and method for treating hematologic cancers | ETV6, BCL6, XPA | MEN1 473/4885KMT2A 2095/4885TDP1 1496/4885 |
| US-11426379-B2 | Combination of local and systemic therapies for enhanced treatment of dermatologic conditions | CYP24A1, CYP2R1, IL23R | MEN1 4290/4885KMT2A 3950/4885TDP1 2213/4885 |
| US-11975106-B2 | Uses of halogenated xanthenes in oncology and virology | IFNG, IRF3, IFNAR1 | MEN1 958/4885KMT2A 3072/4885TDP1 943/4885 |
| US-12281180-B2 | Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same | WNT1, WNT3, WNT3A | MEN1 1000/4885KMT2A 4855/4885TDP1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.